Stock TBPH THERAVANCE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Real-time Estimate Cboe BZX
Other stock markets
 11:04:42 2024-04-18 am EDT 		5-day change 1st Jan Change
9.48 USD -0.42% Intraday chart for Theravance Biopharma, Inc. +5.38% -16.28%
Apr. 12 Sector Update: Health Care Stocks Lower Friday Afternoon MT
Apr. 12 Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Lower Friday Afternoon
MT
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy
MT
BTIG Starts Theravance Biopharma With Buy Rating, $21 Price Target
MT
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
PR
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.
CI
Transcript : Theravance Biopharma, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Theravance Bio: Q4 Earnings Snapshot
AQ
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M
MT
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PR
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Theravance Biopharma to Participate in an Upcoming Investor Conference
PR
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
PR
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint
MT
Top Premarket Decliners
MT
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
PR
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease
CI
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed.
CI
Theravance Biopharma : Material Event - Form 8-K
PU
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors
CI
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TBPH Stock
  4. News Theravance Biopharma, Inc.